September 2012 in “International Current Pharmaceutical Journal” In this study, CHOP chemotherapy for intermediate grade Non-Hodgkin's Lymphoma showed predictable toxicities but was generally well tolerated without treatment interruption among most patients.
5 citations
,
July 2007 in “PubMed” This report describes a case of alopecia totalis associated with lopinavir/ritonavir in an HIV-positive patient, which reversed after discontinuation of the drug.
17 citations
,
April 2023 in “British Journal of Dermatology” This study suggests that off-label use of baricitinib in children under 12 with alopecia areata may improve hair regrowth, but further research is needed to confirm efficacy and safety.
April 2025 in “Frontiers in Pharmacology” This study found that targeting RARβ and RXRA with CANA, in combination with MPA, could help overcome progestin resistance by restoring BAX levels and downregulating CRABP2, suggesting a novel strategy for improving clinical efficacy in this context.
9 citations
,
August 2024 in “Journal of Drugs in Dermatology” In this study, researchers found no evidence of increased prevalence of pericardial effusions in alopecia patients treated with low-dose oral minoxidil compared to those not receiving minoxidil, based on point-of-care ultrasound evaluations.
November 2025 in “Mendeley Data” This study observed that JAK inhibitor therapy may be safely administered to patients with alopecia areata and latent HBV or stable TB, without reactivation of these infections, when appropriate monitoring and prophylaxis are used.
4 citations
,
May 2018 in “Journal of Neuro-Ophthalmology” This review describes the evolution of treatments for relapsing multiple sclerosis, highlighting that while newer potent monoclonal agents can potentially achieve disease remission, they also pose moderate to severe adverse event risks that healthcare providers must understand.
August 2009 in “Australian Prescriber” This article discusses dutasteride, a new drug for managing benign prostatic hyperplasia, and highlights the need for further experience to confirm its safety and efficacy.
May 2023 in “Reactions Weekly” January 2013 in “Reactions Weekly” July 2026 in “Skin Appendage Disorders” In this study, patients with treatment-refractory alopecia areata who received oral ritlecitinib 50 mg daily experienced significant hair regrowth, with 52.6% achieving complete scalp regrowth and improved Severity of Alopecia Tool scores, indicating its potential effectiveness in real-world settings.
January 2024 in “Journal of Crohn's and colitis” This study reports that JAK inhibitors were effective in inducing remission in ulcerative colitis patients and presented an acceptable safety profile with a range of manageable side effects.
6 citations
,
June 1983 in “Cancer” This study found that a chemotherapy regimen combining CMFVP and ACP treatments for unresectable metastatic breast cancer yielded a 66.7% overall response rate, with premenopausal women responding more favorably than postmenopausal women.
26 citations
,
March 2015 in “American journal of clinical dermatology” This study found that systemic mycophenolate mofetil and topical clobetasol were equally effective at reducing lichen planopilaris activity over six months, but satisfaction differed between the treatments.
1 citations
,
October 2025 in “Cureus” In this case report, a 30-year-old male with alopecia universalis and autoimmune conditions experienced treatment failure with JAK inhibitors, including ritlecitinib, and developed severe musculoskeletal pain, indicating a potential novel adverse effect that warrants further pharmacovigilance.
10 citations
,
October 2018 in “Neurology Neuroimmunology & Neuroinflammation” This case report describes a 31-year-old woman experiencing alopecia areata as a potential side effect of alemtuzumab treatment for relapsing-remitting MS.
79 citations
,
January 1982 in “The American Journal of Medicine” This study reports that VP-16-213 (etoposide) shows significant therapeutic activity in several cancers including small cell bronchogenic carcinoma and certain leukemias, with hematologic toxicity being the primary side effect.
August 2022 in “Journal of Investigative Dermatology” Baricitinib reduces inflammation and mitochondrial damage in skin cells.
Minoxidil can cause hair growth as a side effect.
January 1978 in “Clin-Alert” A document listed serious side effects from various drugs, including deaths and diseases, emphasizing the importance of being aware of drug side effects.
31 citations
,
April 2016 in “Journal of the American Academy of Dermatology” Oral dexamethasone may help regrow hair in adults with alopecia totalis and universalis.
February 2026 in “Oncology Reviews” This review highlights the promising clinical outcomes of sacituzumab tirumotecan (sac-TMT), an antibody-drug conjugate for breast cancer that targets TROP2, demonstrating improved response rates and progression-free survival, with manageable safety concerns including primarily mild-to-moderate nausea and alopecia.
May 2025 in “International Journal of Trichology” This retrospective study in a tertiary hair clinic concluded that routine monitoring of heart rate, weight, liver, and kidney function is not necessary for asymptomatic patients with normal baseline values undergoing low-dose oral minoxidil treatment, although monitoring is advised for those with preexisting renal impairment.
May 2021 in “Journal of the Endocrine Society” This case study highlights the overlooked condition of opioid-induced adrenal insufficiency, emphasizing the need for increased clinician awareness of its potential prevalence in chronic opioid users.
November 2010 in “Clin-Alert” Monitoring for adverse effects in clinical treatments is crucial.
In this study, researchers developed isotretinoin-loaded Delonix polymeric nanoparticles that target hair follicles and found they effectively sustained drug release, reduced IL-6 production in vitro without inhibiting P. acnes, and may prevent isotretinoin-related skin irritation in vivo in Wistar rats.
10 citations
,
January 2014 in “Journal of Pediatric Endocrinology and Metabolism” This study identified three new mutations in the VDR ligand-binding domain that may cause dysfunction, and noted that oral calcium and calcidol treatment was effective, but only one patient experienced hair growth.
52 citations
,
July 1998 in “Urology” This study found that liarozole is more effective than cyproterone acetate for improving PSA response and survival in metastatic prostate cancer after first-line endocrine therapy, while maintaining quality of life.
2 citations
,
July 2019 in “PLOS ONE” This study found that the CYP3A4 rs4646437 genotype was significantly associated with ALT elevation in Japanese patients undergoing asunaprevir plus daclatasvir therapy for chronic HCV infection, suggesting genotyping may help in monitoring patients safely.
February 2026 in “Indian Journal of Skin Allergy” This article reviews the clinical efficacy of Ruxolitinib cream for skin conditions, reporting significant improvements in atopic dermatitis and vitiligo, with minimal systemic absorption and a favorable safety profile, compared to placebo.